Clinical trial · Observational
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments: Observational Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer. With the increasing application of preoperative treatments (chemotherapy and chemoradiotherapy), the issues concerning how are the immuno-nutrition index be altered under the effects of perioperative treatments and what are the clinical values of these index should be clarified.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Neoadjuvant Chemoradiotherapy | — | UNRESOLVED | — |
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
| Nutrition Aspect of Cancer | — | UNRESOLVED | — |
| Systemic Inflammatory Response Syndrome (SIRS) | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- naCT
- description
- Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
- label
- naCRT
- description
- Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
Primary outcomes (1)
- measure
- Pathological response
- timeFrame
- One month after surgery
- description
- Pathological response
Secondary outcomes (4)
- measure
- 3-years overall survival
- timeFrame
- Three years after surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed adenocarcinoma * Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy * Diagnosed clinical advanced gastric cancer or esophagogastric cancer Exclusion Criteria: * Lack of immuno-nutrition data
References
Publications (0)
Data not yet available